source
- ai3Bio raises $48 million to develop T-cell targeting therapy for autoimmune diseaseai3Bio announced its emergence from stealth mode after securing $48 million in Series A funding. The round was led by UPMC Enterprises and Ziff Capital Partners and combines technology from Corner…
- Roche halts obesity antibody emugrobart after negative phase 2 interim readoutRoche has stopped development of its obesity antibody emugrobart after an interim analysis of a phase 2 trial indicated a low chance of meeting the study endpoints. The antibody, designed to block…